| PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function S Whelan, E Ophir, MF Kotturi, O Levy, S Ganguly, L Leung, I Vaknin, ... Cancer immunology research 7 (2), 257-268, 2019 | 142 | 2019 |
| Tissue‐resident Eomeshi T‐betlo CD56bright NK cells with reduced proinflammatory potential are enriched in the adult human liver C Harmon, MW Robinson, R Fahey, S Whelan, DD Houlihan, ... European journal of immunology 46 (9), 2111-2120, 2016 | 139 | 2016 |
| Myeloid engraftment in humanized mice: impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain AM Coughlan, C Harmon, S Whelan, EC O'Brien, VP O'Reilly, P Crotty, ... Stem cells and development 25 (7), 530-541, 2016 | 133 | 2016 |
| Therapeutic targeting of checkpoint receptors within the DNAM1 axis Z Alteber, MF Kotturi, S Whelan, S Ganguly, E Weyl, DM Pardoll, J Hunter, ... Cancer discovery 11 (5), 1040-1051, 2021 | 42 | 2021 |
| PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 (+) T-cell Function. Cancer Immunol. Res. 2019; 7: 257–268. doi: 10.1158/2326-6066 S Whelan, E Ophir, MF Kotturi, O Levy, S Ganguly, L Leung, I Vaknin, ... CIR-18-0442.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 24 | |
| COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade K Hansen, S Kumar, K Logronio, S Whelan, S Qurashi, HY Cheng, ... Cancer Immunology, Immunotherapy 70 (12), 3525-3540, 2021 | 20 | 2021 |
| PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia J Li, S Whelan, MF Kotturi, D Meyran, C D’Souza, K Hansen, S Liang, ... Haematologica 106 (12), 3115, 2021 | 19 | 2021 |
| A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. A Sharp, A Williams, SP Blagden, ER Plummer, D Hochhauser, M Krebs, ... Journal of Clinical Oncology 40 (16_suppl), TPS2691-TPS2691, 2022 | 8 | 2022 |
| 778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and IO refractory metastatic solid tumors B Wilky, K Margolin, RE Sanborn, S O'Day | 6* | 2022 |
| Triple combination antibody therapies S Liang, L Leung, S Whelan, M Kotturi, E Ophir, A Machlenkin, Z Alteber, ... US Patent 11,225,523, 2022 | 5 | 2022 |
| 98 NX-0255, a small molecule CBL-B inhibitor, expands and enhances tumor infiltrating lymphocytes (TIL) for use in adoptive cancer immunotherapy S Whelan, J Gosling, M Mani, F Cohen, A Tenn-McClellan, J Powers, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 5 | 2021 |
| Cbl inhibitors and compositions for expansion of immune cells J Gosling, AT Sands, SA Whelan, M Lotze US Patent App. 17/030,258, 2021 | 5 | 2021 |
| PB2099: A first-in-human phase 1 trial of NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies including Richter transformation DLBCL A Sharp, A Williams, S Blagden, R Plummer, D Hochhauser, MG Krebs, ... HemaSphere 6, 1970-1971, 2022 | 4 | 2022 |
| BRAFV600E-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism P Rzasa, S Whelan, P Farahmand, H Cai, I Guterman, R Palacios-Gallego, ... Communications Biology 6 (1), 962, 2023 | 3 | 2023 |
| 670 correlation of durability of response with best response or early discontinuation: a post hoc analysis of the garnet endometrial cancer cohorts L Gilbert, K Moore, V Samouëlian, C Mathews, MP Barretina-Ginesta, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies E Girda, E Zsiros, J Nakayama, S Whelan, S Nandakumar, S Rogers, ... J Clin Oncol 40, TPS5602, 2022 | 2 | 2022 |
| Harnessing the link between BRAFV600E and metabolism in colorectal cancer S Whelan University of Leicester, 2022 | 1 | 2022 |
| Anti-pvrig/anti-tigit bispecific antibodies and methods of use AW Drake, S Kumar, S Mitra, A SALLES, S Whelan, A Kashyap, K Akama, ... | 1 | 2021 |
| Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Immune Checkpoint PVRIG E Ophir, O Levy, S Ganguly, M Kotturi, I Vaknin, L Dassa, M Azulay, ... POS 4, 169, 2017 | 1 | 2017 |
| COM902, a novel therapeutic antibody targeting TIGIT augments t cell function and the activity of PVRIG pathway blockade in vitro and in vivo K Logronio, S Qurashi, S Whelan, K Hansen, S Kumar, L Leung, ... Prostate 21 (71), 19, 0 | 1 | |
